These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2113890)

  • 1. Dealing with discounting. An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase.
    Martens L; van Doorslaer E
    Int J Technol Assess Health Care; 1990; 6(1):139-45. PubMed ID: 2113890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 6. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of myocardial infarction in the elderly: admission and outcome on a coronary care unit.
    Haigh R; Castleden M; Woods K; Fletcher S; Bowns I; Gibson M; Soper J
    Health Trends; 1991-1992; 23(4):154-7. PubMed ID: 10117736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands.
    Vermeer F; Simoons ML; de Zwaan C; van Es GA; Verheugt FW; van der Laarse A; van Hoogenhuyze DC; Azar AJ; van Dalen FJ; Lubsen J
    Br Heart J; 1988 May; 59(5):527-34. PubMed ID: 3132962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy.
    van Klaveren D; Wong JB; Kent DM; Steyerberg EW
    Med Decis Making; 2017 Oct; 37(7):770-778. PubMed ID: 28854143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on "Dealing with discounting".
    Johannesson M; Levin LA
    Int J Technol Assess Health Care; 1991; 7(4):651-6. PubMed ID: 1778716
    [No Abstract]   [Full Text] [Related]  

  • 13. The costs and benefits of community thrombolysis for acute myocardial infarction : a decision-analytic model.
    Vale L; Steffens H; Donaldson C
    Pharmacoeconomics; 2004; 22(14):943-54. PubMed ID: 15362930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 15. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and quality of life: thrombolysis and primary angioplasty.
    Goldman L
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):38S-41S. PubMed ID: 7775713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial infarction, thrombolytic therapy, and economics.
    Conti RC
    Clin Cardiol; 1993 Sep; 16(9):635. PubMed ID: 8242906
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG; Chinnis JO; Ulvila JW
    Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.